Hormone Sensitive Prostate Cancer Clinical Trials in Nanjing, Jiangsu
2 recruitingNanjing, Jiangsu, China
Showing 1–2 of 2 trials
Recruiting
Phase 3
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Prostate CancerCancer of the ProstateHormone Sensitive Prostate Cancer+1 more
Pfizer1,000 enrolled295 locationsNCT07028853
Recruiting
Phase 3
Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
Chemotherapy EffectMetastatic Prostate CancerHormone Sensitive Prostate Cancer
The First Affiliated Hospital with Nanjing Medical University200 enrolled1 locationNCT05983783